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Many clinical and animal studies suggest that vitamin D and
its metabolites have beneficial effects in the cardiovascular
and renal systems. Using immunologic and enzymatic assays,
vitamin D receptor and 25 hydroxyvitamin D3 1a-hydroxylase
activity were found in inner medullary collecting duct (IMCD)
cells suggesting an autocrine/paracrine role in this nephron
segment. In this study, we examined the ability of 1,25
dihydroxyvitamin D3 (1,25(OH)2D3) to regulate the
expression of the vasculoprotective natriuretic peptide
receptor-A gene in these cells in culture. Treatment of the
cells with 1,25(OH)2D3 caused a doubling of natriuretic
peptide-dependent cyclic guanosine monophosphate
production and a significant increase in natriuretic peptide
receptor-A protein expression. This was accompanied by
significant increases in receptor mRNA levels and gene-
promoter activity. Mutation of a vitamin D response element,
positioned upstream from the gene start site, resulted in a
complete loss of 1,25(OH)2D3-dependent induction but not
the induction by hypertonic stimuli. Introduction of small
interfering RNA directed against the vitamin D receptor into
the IMCD cells resulted in decreased natriuretic peptide
receptor-A gene promoter activity and protein. The increase
in this receptor expression may account for some of the
reported beneficial effect of 1,25(OH)2D3 on the
cardiovascular system and kidney.
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Vitamin D, or more specifically its polar metabolite 1,25
dihydroxyvitamin D3 (1,25(OH)2D3), is thought to
play a significant role in the regulation of growth and
function in the cardiovascular system and kidney.1 Vitamin D
deficiency in rats is associated with hypertension and
cardiac hypertrophy2 and expansion of the interstitial
compartment of the myocardium.3 Treatment of cultured
neonatal cardiac myocytes with 1,25(OH)2D3 effectively
reverses endothelin-induced hypertrophy in this in vitro
model.4 Genetic deletion of the vitamin D receptor5 results in
a mouse with hyper-reninemic hypertension6 and cardiac
hypertrophy.7
Subsets of human hypertensive patients have low 25-
hydroxyvitamin D3 (25(OH)D3) levels,8 as do patients with
congestive heart failure9,10 and peripheral vascular disease.11
Treatment of small groups of hypertensive patients with
1,25(OH)2D3 has been shown to lower blood pressure,
12–14
whereas treatment of patients with end-stage renal disease on
dialysis with 1,25(OH)2D3 leads to regression of left
ventricular hypertrophy in this patient population.15 Further-
more, retrospective analysis of dialysis patients treated with
either 1,25(OH)2D3
16 or paricalcitol,17 a 1,25(OH)2D3
analogue with reduced calcemic potential, reduced mortality
compared with controls. As cardiovascular disease is the
leading cause of death in patients with end-stage renal disease
on dialysis, it can be inferred that these vitamin D receptor
(VDR) ligands are positively impacting cardiovascular disease
in this patient group.
The inner medullary collecting duct (IMCD) is positioned
at the distal terminus of the nephron and, despite the fact
that it samples less than 5% of filtered sodium load, it plays
a pivotal role in determining the final urinary sodium
concentration.18 Sodium handling in this nephron segment is
highly regulated by a number of hormones including atrial
natriuretic peptide (ANP). ANP is produced in the heart
and acts by binding to natriuretic peptide receptor type A
(NPR-A) in target tissues and triggering increased synthesis
of cyclic guanosine monophosphate (cGMP). Binding of
circulating ANP or its locally produced homologue urodila-
tin19 to NPR-A on IMCD cells leads to an increase in urinary
sodium excretion through a cGMP-dependent mechanism.20
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We have recently shown that treatment of rat aortic
smooth muscle cells with 1,25(OH)2D3 leads to an increase
in expression and activity of NPR-A in these cells.21 In this
study, we demonstrate that VDR, present in IMCD cells,
triggers a similar increase in NPR-A activity and gene
expression through a transcriptional mechanism and that
suppression of endogenous VDR levels reverses this response.
We hypothesize that low levels of 1,25(OH)2D3 or VDR-
dependent activity may contribute to sodium retention seen
in disorders like congestive heart failure and salt-sensitive
hypertension through a reduction in NPR-A activity.
RESULTS
Vitamin D has been suggested to play a role in the regulation
of renal calcium handling, possibly through induction of
calcium transport proteins in different nephron segments.22
To assess the presence of endogenous VDR and 25(OH)D3
1a-hydroxylase in cultured IMCD cells, we examined
extracts of cells cultured for 48 h in the presence or absence
of 1,25(OH)2D3 by Western blot analysis. As shown in
Figure 1, VDR and 25(OH)D3 1a-hydroxylase were readily
demonstrable in these extracts. Interestingly, pretreatment
with 1,25(OH)2D3 resulted in a dose-dependent increment
in VDR levels (2–2.5-fold increase relative to control) over
a physiologically relevant range of ligand concentrations.
1,25(OH)2D3 treatment had no effect on 25(OH)D3
1a-hydroxylase expression. To demonstrate 25(OH)D3
1a-hydroxylase activity in IMCD cells, we measured
1,25(OH)2D3 production and release in the medium of
cultured IMCD cells following addition of 25(OH)D3
substrate. Compared with the substrate-free cultures, there
was a dramatic increase in 1,25(OH)2D3 levels in the
medium of the 25(OH)D3-treated group (3.6370.47 vs
11.9472.17 pg/ml, n¼ 3 Po0.01), demonstrating the ability
of IMCD cells to covert 25(OH)D3 to 1,25(OH)2D3.
We next assessed the effect of 1,25(OH)2D3 treatment on
the ability of these IMCD cells to respond to ANP, as a
surrogate marker of NPR-A activity. As shown in Figure 2,
pretreatment with 1,25(OH)2D3 or the 1,25(OH)2D3
analogue, RO-25-6760, elicited a doubling in ANP-depen-
dent cGMP generation and 3–4-fold increase in NPR-A
protein expression in these cells.
The increase in NPR-A activity was accompanied by
an increase in NPR-A mRNA levels in IMCD cells. Both
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Figure 1 | VDR and 25(OH)D3 1a-hydroxylase are expressed in
IMCD cells and VDR is upregulated by 1,25(OH)2D3 (D3) in dose-
dependent fashion. VDR and 25(OH)D3 1a-hydroxylase expression
levels were normalized for glyceraldehyde-3-phosphate
dehydrogenase protein level. Representative autoradiographs
(a for VDR, b for 25(OH)D3 1a-hydroxylase) and pooled data (c) from
3–5 independent experiments are shown. *Po0.01 vs control.





























































Figure 2 | 1,25(OH)2D3 stimulates NPRA expression and activity.
1,25(OH)2D3 and its analogue, RO-27-6760, increase (a) ANP-induced
cGMP level and (b) NPR-A protein expression in IMCD cells. Data from
3–5 independent experiment are shown. *Po0.01 vs control.
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1,25(OH)2D3 and RO-25-6760 elucited a significant increase
in NPR-A mRNA levels, which peaked B3-fold above the
controls treated with vehicle alone (Figure 3).
The increase in NPR-A transcript levels was linked to an
increase in NPR-A gene transcriptional activity. As shown in
Figure 4a, 1,25(OH)2D3 treatment led to B2.5-fold increase
in NPR-A gene promoter activity over a physiological
concentration range for the ligand. Transfection of additional
exogenous receptor (Figure 4b) led to further amplification
of the 1,25(OH)2D3-dependent stimulation of promoter
activity.
To explore the VDR dependence of this stimulatory
activity, we used a small interfering RNA (siRNA) strategy
directed against endogenous VDR-coding sequence. Treat-
ment of IMCD cells with siRNAs directed against the VDR
resulted in a decrease in VDR levels in these cells (Figure 5a)
with two of the three siRNAs (V1 and V2, but not V3) and a
reduction in 1,25(OH)2D3-dependent stimulation of NPR-A-
promoter activity (Figure 5b). A negative control siRNA,
which lacked targeting capability, was without effect.
VD-dependent induction of NPR-A gene-promoter activ-
ity was virtually completely dependent on the presence of a
VDR element (VDRE) located B495 bp upstream from the
transcription start site in the promoter (Figure 6a). This was
also true for RO-25-6760; however, the VDRE mutation had
no effect on the osmotic induction of promoter activity by
NaCl or sucrose.23 Furthermore, addition of 1,25(OH)2D3
to either NaCl or sucrose resulted in a modest, albeit not
additive, increase in promoter activity which was only
partially reduced in the VDRE-mutant promoter-driven
reporter. Electrophoretic mobility shift assay of IMCD cell
extracts demonstrated that 1,25(OH)2D3 promoted VDR/
retinoid X receptor (RXR) binding to oligonucleotides
harboring the NPR-A VDRE (Figure 6b). The binding was
eliminated in the presence of unlabeled wild-type DNA
sequence; however, unlabeled, mutated sequence was unable
to compete.
DISCUSSION
The findings presented above support our hypothesis that
1,25(OH)2D3 stimulates transcription of the gene encoding
NPR-A in IMCD cells. It does so through a mechanism that
requires the vitamin D receptor and the presence of a
functional VDRE positioned B495 bp upstream from the
NPR-A gene transcription start site. This supports our earlier
demonstration of 1,25(OH)2D3-dependent stimulation of
NPR-A gene regulation in rat aortic smooth muscle cells21
and the findings of Li et al.24 describing reduced NPR-A gene
expression in the kidneys of VDR / mice. Of note,
we have shown here that IMCD cells express 25(OH)D3
1a-hydroxylase, the enzyme which is responsible for conver-
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Figure 3 | 1,25(OH)2D3 stimulates NPR-A gene expression.
Northern blot analysis of RNA from cultured IMCD cells treated with
(a) 1,25(OH)2D3 or (b) RO-27-6760 using NPR-A cDNA probe. NPR-A
signal was normalized to 18S ribosomal RNA signal following
rehybridization of the same membrane with 18S probe.







































Figure 4 | 1,25(OH)2D3 amplifies NPR-A transcription by
increasing its promoter activity. (a) One microgram of 1575
NPR-A-Luc with 0.5 mg Renilla-Luc were cotransfected into IMCD
cells. After transfection for 24 h, cells were treated with different
concentrations of 1,25(OH)2D3 for 48 h. (b) IMCD cells were
transfected with NPR-A-Luc and Renilla-Luc with or without 0.1 or
0.5mg of VDR expression vector. Twenty-four hours after transfection,
cells were treated with 108 M 1,25(OH)2D3 for 48 h. NPR-A luciferase
activity was normalized for Renilla-Luc activity in the individual
cultures. The experiments were repeated three times. *Po0.01 vs
control.
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Figure 5 | VDR siRNA reduces basal VDR expression and
NPR-A-Luc activity in IMCD cells. Three different VDR siRNAs
(V1, V2, and V3) and control siRNA (C) were individually transfected
into IMCD cells. Forty-eight hours later, cells were harvested and total
protein was assayed for VDR or glyceraldehyde-3-phosphate
dehydrogenase expression by Western blot analysis. VDR expression
was normalized for glyceraldehyde-3-phosphate dehydrogenase
protein levels. (a) Representative results and pooled data (n¼ 3).
In a separate experiment, the VDR siRNAs and control siRNA were
individually cotransfected with 1575 NPR-A-Luc and Renilla-Luc
into IMCD cells and cultured for 48–72 h. Cells were collected
and luciferase activities were measured. NPR-A-Luc activity was
normalized for Renilla luciferase activity in individual samples.
(b) Pooled data (n¼ 3). *Po0.01 vs control.
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sion of 25(OH)D3 to its more polar and bioactive metabolite,
1,25(OH)2D3. Endogenous 1,25(OH)2D3 in IMCD cells
probably contributes to the maintenance of basal NPR-A
levels. Local production of 1,25(OH)2D3 may accommodate
the need for relatively high ligand concentrations (above
circulating plasma concentrations) that we observed in this
study (see Figures 2 and 3).
Recent studies have suggested that 1,25(OH)2D3 may
play an important role in the regulation of a variety of
physiological processes, including skin and hair follicle
development,25,26 growth and function in the cardiovascular
system,4,27 and the control of immune function and
inflammatory response.28,29 All of these are largely indepen-
dent of the more classical, and better understood, effects of
1,25(OH)2D3 on mineral homeostasis and bone metabolism.
Observational studies suggest that the presence of hyper-
tension30 and susceptibility to certain types of infections
like tuberculosis,31–33 correlate inversely with the ability to
generate endogenous vitamin D.
In the cardiovascular system, 1,25(OH)2D3 has been
shown to regulate proliferative activity in vascular smooth
muscle cells in culture,28 to antagonize cardiac myocyte
hypertrophy in an in vitro model,4 to reduce blood pressure
in selected groups of human hypertensives,13,14 and to reverse
hypertrophy in patients with end-stage renal disease on
dialysis.15 Furthermore, treatment of dialysis patients with
1,25(OH)2D3,
16 or a 1,25(OH)2D3 analogue with reduced
calcemic potential,17 leads to improvement in survival,
a variable which is heavily dependent on the presence of
cardiovascular disease in this population. Collectively, these
studies support the notion that 1,25(OH)2D3, at least at
nontoxic concentrations, exerts a beneficial effect in promot-
ing cardiovascular health.
Heart failure is a complex disease of pump function
and neurohormonal dysregulation that is characterized by
inadequate delivery of blood flow to vascularized tissues.
Heart failure is associated with reduced plasma levels of
25(OH)D3 and 1,25(OH)2D3
9,10 and treatment of heart
failure patients with 1,25(OH)2D3 has been shown to
diminish plasma levels of cytokines (e.g., tumor necrosis
factor) that are associated with myocardial inflammation.34
Heart failure is characterized by resistance to natriuretic
peptides, a phenomenon which may, in part, reflect altered
NPR function.35 The excessive sodium retention asso-
ciated with heart failure is exacerbated by inhibition of
NPR-A activity36,37 and myocardial NPR-A is thought to
mediate a ligand-dependent antagonism of hypertrophy
and fibrosis in the myocardial wall.38 By inference,
1,25(OH)2D3 insufficiency or bonafide 1,25(OH)2D3 defi-
ciency could, through an indirect effect to reduce NPR-A
activity, play an important role in accelerating development
of heart failure, or salt-sensitive hypertension, and in




The cGMP radioimmunoassay kit was obtained from Perkin-Elmer
Life Sciences (Boston, MA, USA). ANP was purchased from
American Peptide (Sunnyvale, CA, USA). R0-25-6760 (1,25-
dihydroxy-16-ene-23-yne-26,27-hexafluoro-19-nor-cholecalciferol)
was a kind gift of M Uskokovic (Roche Pharmaceuticals, Nutley, NJ,























































































Figure 6 | Effects of sucrose, NaCl, and 1,25(OH)2D3 or
RO-25-6760 on NPR-A promoter activity and the effect of
mutation of the VDRE on this promoter. (a) IMCD cells were
transfected with wild-type or VDRE-mutated 1575 NPR-A Luc,
together with Renilla-Luc, and incubated with 108 M 1,25(OH)2D3
or 109 M RO-27-6760 for 48 h, or 75 mM NaCl or 150 mM sucrose
for 24 h or a combination of 1,25(OH)2D3 and hypertonic agents.
Firefly luciferase activity was normalized for Renilla luciferase activity.
Pooled data (n¼ 3–5) are shown. *Po0.01 vs control. (b) 1,25(OH)2D3
promotes binding of VDR to VDRE on NPR-A promoter in IMCD
cells. Three micrograms of nuclear extract from sham- vs VDR/
RXR-transfected IMCD cells in the presence or absence of 108 M
1,25(OH)2D3 were incubated with
32P-labeled NPR-A4
oligonucleotide alone or in combination with unlabeled NPR-A4
or M2-NPR-A4 oligonucleotides and separated by electrophoretic
mobility shift assay. Representative autoradiograph from three
different experiments is shown.
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CA, USA). VDR antibody (cat no. sc-1008) and glyceraldehyde-3-
phosphate dehydrogenase antibody (cat no. sc-32233) were
purchased from Santa Cruz Biotechnology (SantaCruz, CA, USA).
25-hydroxyvitamin D 1a-hydoxylase antibody (cat no. PC290) was
from The Binding Site (Birmingham, UK). NPR-A antibody (cat no.
ab14356) was obtained from Abcam Inc. (Cambridge, MA, USA).
Isolation and culture of rat IMCD cells
Adult Sprague–Dawley rats were killed by CO2 narcosis, followed
by bilateral thoracotomy in compliance with a protocol approved
by the University of California at San Francisco Committee on
Animal Research. The inner medullary tissue from each kidney was
dissected free from the outer medulla, minced, and digested with
1 mg/ml collagenase at 371C with gentle agitation during each
30-min cycle. IMCD cells were enriched in the preparation using
hypotonic lysis as described previously.39 Cells were resuspended in
medium-1 (1:1 mixture of Dulbecco’s modified Eagle’s medium and
Ham’s F-12 medium supplemented with 10% fetal bovine serum,
42 mM sodium bicarbonate, 100 IU/ml penicillin, and 100mg/ml
streptomycin)24 and seeded onto culture plates. After 24 h, the cells
were placed in K-1 medium (1:1 mixture of Dulbecco’s modified
Eagle’s medium and Ham’s F-12 medium supplemented with 10 mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic (HEPES) (pH
7.4), 42 mM sodium bicarbonate, 5 mg/ml insulin, 50 nM hydro-
cortisone, 5 mg/ml transferrin, 5 pM triiodothyronine, 100 IU/ml
penicillin, and 100 mg/ml streptomycin)24 and cultured for 3–4 days.
Measurement of 25(OH)D3 1a-hydroxylase activity in
IMCD cells
Seventy percent confluent IMCD cells in six-well plates were treated
with 107 M 25(OH)D3 for 24 h. Medium (2 ml) from cultured cells
was collected and 25(OH)D3 1a-hydroxylase activity was assessed in
0.1 ml delipidated medium by measurement of 1,25(OH)2D3 using
a 1,25(OH)2D3 enzyme-linked immunosorbent assay kit
40,41 (Im-
munodiagnostics Systems Inc.; Fountain Hills, AZ). This enzyme-
linked immunosorbent assay kit is specific for 1,25(OH)2D3 and has
minimal reactivity with other vitamin D metabolites (e.g., 0.009%
cross-reactivity with 25(OH)D3). To control for cross-reactivity of
25(OH)D3 or nonenzymatic generation of 1,25(OH)2D3 in the
assay, medium containing the same concentration of 25(OH)D3 was
incubated under identical condition but without cells. The assay was
performed by following the protocol provided by Immunodiagnos-
tics Systems Inc.
Measurement of ANP-stimulated cGMP levels
IMCD cells were grown to approximately 80% confluence and
treated with 109–10–7 M 1,25(OH)2D3 for 48 h. For measurement of
ANP-stimulated cGMP accumulation, cells were washed three times
with prewarmed phosphate-buffered saline and incubated with
0.5 ml of Dulbecco’s modified Eagle’s medium that contained
0.5 mM isobutylmethylxanthine and 10 mM HEPES (pH 7.4) for
10 min at 371C. The incubation was continued for another 10 min
with the addition of 10–7 M ANP to the medium. The reaction was
stopped by the removal of medium and addition of 0.3 ml of 10%
trichloroacetic acid. The extraction was continued for 30 min at 41C.
The contents of the plate were collected and centrifuged to pellet
particulate material. The supernatant fraction was extracted four
times with 0.5 ml of water-saturated ether. cGMP levels were
determined by radioimmunoassay after acetylation of the samples
and standards using a commercial antibody and [125I]cGMP as
tracer.
RNA isolation and Northern blot analysis.
IMCD cells were cultured and treated with 1,25(OH)2D3 or RO-25-
6760 at different concentrations, as indicated in the individual figure
legends. Total RNA was prepared using the RNeasy minikit (Qiagen,
Valencia, CA, USA). Denatured RNA was separated on a gel,
transferred to nitrocellulose filters, and hybridized to radiolabeled
cDNA as described previously. A 1.2-kb EcoRI fragment of the rat
NPR-A cDNA was radiolabeled using the primer-it RMT kit
(Stratagene, LaDolla, CA, USA) and separated from free nucleotide
using NucTrap push columns (Stratagene). The membranes were
hybridized with 32P-labeled NPR-A cDNA for 1 h at 681C in
hybridization solution provided by Stratagene. All membranes were
subsequently stripped and rehybridized with a radiolabeled 1150-bp
BamHI/EcoRI fragment of 18S ribosomal DNA to permit normal-
ization among samples for differences in RNA loading and/or
transfer to the filter. Hybridization signal was detected by
autoradiography and quantified using Kodak Scientific Imaging
systems.
Site-directed mutagenesis
A VDRE in the 1575 NPR-A promoter was identified (472 50-GA
GCCAGAGTCCGGGTTACCCAGTCCATCAATG-30 504; element
in italics and underlined) and mutations (472 50-GAGCCAGAGT
CCGtGTTgCCCAtTCCATCAATG-30 504; mutated bases in lower
case letters) were created in –1575 NPR-A-Luc by site-directed
mutagenesis using a commercial kit (Stratagene), as reported
previously.21
Transfection and luciferase assay
Cells were plated in six-well plates and grown to about 70%
confluence. At that time, transfection was performed with lipofectin
reagent (Invitrogen Corp, Carlsbad, CA, USA) using a protocol
recommended by the manufacturer. One microgram of wild-type-
or VDRE-mutated 1575 NPR-A-Luc together with 0.5 mg Renilla-
Luc were introduced into each well. The DNA–liposome suspension
was incubated with the cultures for 5–6 h at 371C in Opti-MEMI
reduced serum medium (Invitrogen Corp). The suspension was
then removed and replaced with K-1 medium for the ensuing 24 h,
at which point cells were treated with 1,25(OH)2D3 for 48 h.
Luciferase activity was measured using the Dual-Luciferases
reporter assay system (Promega, Madison, WI, USA). Transfection
efficiency was normalized for Renilla luciferase activity in the
individual cultures.
Immunoblotting
The cells were treated with 1,25(OH)2D3 at different concentrations
for 48 h, then scraped into lysis buffer containing protease inhibitors
(1 tablet/50 ml; Roche Applied Science, Indianapolis, IN, USA).
Twenty micrograms of total protein was denatured at 1001C for
3 min, subjected to 10% sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, and transferred onto polyvinylidene fluoride
membranes. The membranes were blocked with 5% nonfat milk
in TBST (50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20)
and probed with a rabbit polyclonal antibody directed against VDR
and a sheep anti-murine 25(OH)D3 1a-hydroxylase. Horseradish
peroxidase-conjugated second antibodies were used to detect
immunoreactive bands using the enhanced chemiluminescence
Western blotting-detection system (Amersham Bioscience, Piscat-
away, NJ, USA). The same membranes were reblotted with anti-
glyceraldehyde-3-phosphate dehydrogenase antibody. VDR and
25(OH)D3 1a-hydroxylase signals were quantified using Kodak
304 Kidney International (2007) 72, 300–306
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Scientific Imaging systems and normalized for glyceraldehyde-3-
phosphate dehydrogenase signal.
To prepare membrane protein, cells were treated with
1,25(OH)2D3 or its analogue for 48 h and then scraped into ice-
cold phosphate-buffered saline containing protease inhibitors. After
brief centrifugation, cells were resuspended in buffer 1 (50 mM Tris,
pH 7.5, 200 mM sucrose, 1 mM ethylenediaminetetraacetic acid, 3 mM
MgCl2, and protease inhibitors) and sonicated. After centrifu-
gation at 500 r.p.m. for 10 min, soluble and membrane fractions
were separated by centrifugation at 80 000 r.p.m. for 1 h at 41C.
The particulate fractions were resuspended in lysis buffer. Fifty
microgram of membrane protein were used for Western blot with
1:1000 NPR-A antibody. The same filter was washed and reprobed
with b tubulin antibody (Santa Cruz, Biotechnology). NPR-A signal
was quantified on a Kodak Image Station and normalized for beta
tubulin signal.
Preparation of Nuclear Extracts and electrophoretic mobility
shift assay
IMCD cells were transfected with 5 mg of human VDR and human
RXR or sham transfected using lipofectin reagent (Invitrogen,
Carlsbad, CA, USA) for 24 h. Cells were changed to K-1 media and
treated with vehicle or 108 M 1,25(OH)2D3 for 48 h. Cells were
lysed with buffer A (10 mM HEPES at pH 7.9, 1.5 mM MgCl2, 10 mM
KCl, 0.5% nonidet P-40, 1 mM dithiothreitol, protease inhibitors) on
ice for 10 min. Lysates were centrifuged for 5 min at 41C. Particulates
were resuspended in buffer C (20 mM HEPES at pH 7.9, 420 mM
NaCl, 1.5 mM MgCl2, 0.2 mM ethylenediaminetetraacetic acid, 25%
glycerol, and the above protease inhibitors) and kept on ice
for 30 min. Nuclear suspensions were centrifuged at 12 800 g for
10 min and the supernatants (nuclear extracts) were used
for electrophoretic mobility shift assay. Oligonucleotides used for
electrophoretic mobility shift assay were as follows (sequence
represents sense strand; italicized represents sequence the putative
VDRE), mutated bases in lower case: NPR-A4 (50-GAGCCAGAG
TCCGGGTTACCCAGTCCATCAATG-3’), M2-NPR-A4 (50-GAGC
CAGAGTCCGtGTTgCCCAtTCCATCAATG-30).21 Nuclear extracts
(3–5 mg) were incubated in binding reaction buffer (10 mM HEPES
at pH 7.9, 50 mM KCl, 0.2 mM ethylenediaminetetraacetic acid,
2.5 mM dithiothreitol, 10% glycerol, and 0.05% nonidet P-40)
containing 1 mg of poly(dI-dC) and 32P-end-labeled double-stranded
wild-type NPR-A4 oligonucleotide at room temperature for 30 min.
For competition experiments, a 50-fold molar excess of unlabeled,
double-stranded oligonucleotide was added to the binding reaction.
All samples were resolved on 4% nondenaturing polyacrylamide
gels. Gels were dried and exposed to X-ray film.
siRNA silencing of VDR gene
Twenty one-nucleotide annealed duplex siRNAs directed against
rat VDR gene sequence (V1 – GCGUAAGAGGAGAUGAUAtt,
V2 – GGAUUCUGAUGACCCGUCUtt, and V3 – GGAGUUCAUCC
UGACAGAUtt; all sense strand) were chemically synthesized and
purified using a commercial source (Amibon, Austin, TX) as was a
negative control siRNA (Ambion) containing a 19-bp scrambled
sequence. The latter sequences have no significant homology to any
known gene sequences from rat. IMCD cells were cultured to
60–70% confluence and then transfected with 100 pmol V1, V2, V3,
or the negative control siRNA using lipofectamine (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s
instructions. After transfection for 48 h, cells were washed and
cellular lysates were prepared and analyzed for VDR expression by
Western blot analysis. In a separate experiment, 1 mg 1575 rat
NPR-A-Luc and 0.5 mg Renilla-Luc were cotransfected with
100 pmol V1, V2, V3, or control siRNA into IMCD cells using
lipofectamine. After 48 h, cells were collected and lysates were
generated for luciferase (firefly and Renilla) assay.
Statistical analyses
Data were analyzed by analysis of variance, using the Newman–Keuls
test to assess significance.
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